Health equity: access to quality services and caring for underserved populations.

Barriers to access to quality services and caring for underserved populations are a call to action for researchers and other key partners to achieve health equity. In order to accomplish this, several key partners play important roles. More participation of younger generations, women and people of color from different contexts should be encouraged and facilitated. This editorial serves to present this journal issue that includes the articles of young women from low- and middle-income countries. Different methodologies are used to demonstrate the problem of access to quality services and care in a comprehensive way. After understanding the public health problems using an equity lens, we need to implement evidence-based interventions to improve the health system response.

Pilot Feasibility Assessment of a Tailored Physical Activity Prescription in Overweight and Obese People in a Public Hospital.

We aimed to evaluate the feasibility of a tailored physical activity (PA) prescription in overweight and obese people in a tertiary hospital in Lima, Peru. A feasibility pre-post-pilot study was conducted using mixed methods. Participants received a tailored prescription scheme for PA that lasted twelve weeks. It included two prescription sessions, three follow-up phone calls, and three evaluations. Primary feasibility outcomes were recruitment, visits, and phone call adherence. Primary intervention outcomes were self-reported PA levels and the 6 min walk test. Out of 228 people invited to participate, 30 were enrolled and received the first session of prescription, 11 went to the second session, and 21 went to the final evaluation; phone call participation decreased progressively during follow-up. There were no differences in the 6th week and the 12th week compared to the baseline for all the measures, except in the 6 min walk test. The participants considered the intervention was well designed, but they suggested complementing it with dietary instructions. The prescription of PA in overweight and obese people is feasible for promoting PA, but its implementation requires refinements to anticipate possible barriers to changing behavior.

The value of process evaluation for public health interventions: field-case studies for non-communicable disease prevention and management in five countries.

Complex interventions are needed to effectively tackle non-communicable diseases. However, complex interventions can contain a mix of effective and ineffective actions. Process evaluation (PE) in public health research is of great value as it could clarify the mechanisms and contextual factors associ-ated with variation in the outcomes, better identify effective components, and inform adaptation of the intervention. The aim of this paper is to demonstrate the value of PE through five case studies that span the research cycle. The interven-tions include using digital health, salt reduction strategies, use of fixed dose combinations, and task shifting. Insights of the methods used, and the implications of the PE findings to the project, were discussed. PE of complex interventions can refute or confirm the hypothesized mechanisms of action, thereby enabling intervention refinement, and identifying implementation strategies that can address local contextual needs, so as to improve service delivery and public health outcomes.

COVID-19's impact on type 1 diabetes management: A mixed-methods study exploring the Peruvian experience.

INTRODUCTION: The COVID-19 pandemic has negatively impacted health services, especially in low-and-middle-income countries, where care for chronic conditions such as diabetes was disrupted. Our study aims to describe the challenges faced by people living with Type 1 diabetes mellitus (T1DM) to access care during the COVID-19 pandemic in Peru. METHODS: A sequential explanatory mixed-method study was conducted between May and September 2020 including health professionals involved in T1DM care, people with T1DM and their caregivers. The study consisted of a quantitative strand to gather general information through electronic surveys and a qualitative strand that involved in-depth interviews. RESULTS: For the quantitative study, we included 105 people with T1DM, 50 caregivers and 76 health professionals. The qualitative study included a total of 31 interviews; 16 people with T1DM, 14 health care professionals, and one representative from the Peruvian Ministry of Health (MoH). People with T1DM faced difficulties accessing consultations, insulin, monitoring devices and laboratory testing during the pandemic. Different phases of the Peruvian health system response were found. Firstly, an initial informal response to addressing T1DM care during the pandemic characterised by local initiatives to ensure continuity of care for people with T1DM. Following from this, a formal response was implemented by the MoH which focussed on reinforcing the primary level of care. Measures included teleconsultations and delivery of medicines, although these were not implemented in all health care establishments. Throughout the pandemic patient associations played an important role in organising and helping to counteract the impact of COVID-19 on people with T1DM. CONCLUSIONS: The Peruvian health care system slowly adapted to the COVID-19 pandemic to provide care for people with T1DM. However, people with T1DM had difficulties to access care. Thus, reinforcement of interventions such as communication between levels of care, teleconsultations and delivery of medicines was urgently needed. Patient associations' capacity to respond should be considered by local authorities and civil society should be part of the health system response.

Design of financial incentive interventions to improve lifestyle behaviors and health outcomes: A systematic review.

Background: Financial incentives may improve the initiation and engagement of behaviour change that reduce the negative outcomes associated with non-communicable diseases. There is still a paucity in guidelines or recommendations that help define key aspects of incentive-oriented interventions, including the type of incentive (e.g. cash rewards, vouchers), the frequency and magnitude of the incentive, and its mode of delivery.  We aimed to systematically review the literature on financial incentives that promote healthy lifestyle behaviours or improve health profiles, and focused on the methodological approach to define the incentive intervention and its delivery. The protocol was registered at PROSPERO on 26 July 2018 ( CRD42018102556). Methods: We sought studies in which a financial incentive was delivered to improve a health-related lifestyle behaviour (e.g., physical activity) or a health profile (e.g., HbA1c in people with diabetes). The search (which took place on March 3 rd 2018) was conducted using OVID (MEDLINE and Embase), CINAHL and Scopus. Results: The search yielded 7,575 results and 37 were included for synthesis. Of the total, 83.8% (31/37) of the studies were conducted in the US, and 40.5% (15/37) were randomised controlled trials. Only one study reported the background and rationale followed to develop the incentive and conducted a focus group to understand what sort of incentives would be acceptable for their study population. There was a degree of consistency across the studies in terms of the direction, form, certainty, and recipient of the financial incentives used, but the magnitude and immediacy of the incentives were heterogeneous. Conclusions: The available literature on financial incentives to improve health-related lifestyles rarely reports on the rationale or background that defines the incentive approach, the magnitude of the incentive and other relevant details of the intervention, and the reporting of this information is essential to foster its use as potential effective interventions.

A mHealth intervention to promote hand-washing and cell phone cleaning in medical residents of a public hospital in Peru.

INTRODUCTION: We explore the limitations to adherence of hand-washing and evaluate the impact of a mHealth intervention for hand hygiene in residents. METHODOLOGY: We explore resident's perspectives about Hospital-acquired infections (HAI) and hand washing. In baseline, participants completed socio-demographic characteristics and hand-washing habits survey. The intervention consisted of sending SMS three times a week for two months about hand hygiene and "five moments" for hand washing. The cultures of hands and cell phones were analyzed at baseline, 2 months and 4 months. We used chi-square and adjusted Generalized Estimating Equations. RESULTS: Five physicians were interviewed and 33 participants were included for quantitative analysis. Critical barriers that hinder hand washing were identified. The proportion of Staphylococcus aureus in hands was 54.5% at baseline and was significantly reduced at 2 months follow-up (p = 0.009), but, benefit was lost when the intervention was discontinued; Escherichia coli and Klebsiella sp. were observed in 22.2% of hands, no changes were noted with intervention. In cell phones, there was a tendency to lower values of bacterial colonization after intervention for Staphylococcus aureus growth. CONCLUSIONS: High prevalence of contamination in hands and phones in medical residents were found. Serious barriers to compliance with hand washing must be overcome. It is possible that prolonged or continuous interventions could be necessary to optimize hand washing and reduce hand and cell phones contamination.

A global perspective on the issue of access to insulin.

The discovery of insulin in 1921 changed the prognosis for people with type 1 diabetes. A century later, availability and affordability of insulin remain a challenge in many parts of the globe. Using the WHO's framework on understanding the life cycle of medicines, this review details the global and national challenges that affect patients' abilities to access and afford insulin. Current research and development in diabetes has seen some innovations, but none of these have truly been game-changing. Currently, three multinational companies control over 95% of global insulin supply. The inclusion of insulin on the WHO's Prequalification Programme is an opportunity to facilitate entry of new companies into the market. Many governments lack policies on the selection, procurement, supply, pricing and reimbursement of insulin. Moreover, mark-ups in the supply chain also affect the final price to the consumer. Whilst expenses related to diabetes are mostly covered by insurance in high-income countries, many patients from low- and middle-income countries have to pay out of their own pockets. The organisation of diabetes management within the healthcare system also affects patient access to insulin. The challenges affecting access to insulin are complex and require a wide range of solutions. Given that 2021 marks the centenary of the discovery of insulin, there is need for global advocacy to ensure that the benefits of insulin and innovations in diabetes care reach all individuals living with diabetes.

[Healthcare challenges for people with diabetes during the national state of emergency due to COVID-19 in Lima, Peru: primary healthcare recommendations]. / Los retos del cuidado de las personas con diabetes durante el estado de emergencia nacional por COVID-19 en Lima, Perú: recomendaciones para la atención primaria.

Patients diagnosed with type 2 diabetes mellitus, who then become infected with SARS-CoV-2, are at greater risk of developing complications from COVID-19, which may even lead to death. Diabetes is a chronic condition that requires continuous contact with healthcare facilities; therefore, this type of patients should have regular access to medicines, tests and appointments with healthcare personnel. In Peru, care and treatment continuity have been affected since the national state of emergency due to COVID-19 began; because many healthcare facilities suspended outpatient consultations. The strategies presented in this study were developed by different Peruvian health providers in the pandemic context to ensure care continuity for people with diabetes. This article provides recommendations to strengthen primary healthcare, because it is the first level of healthcare contact for patients with diabetes.

Las personas con diabetes mellitus tipo 2 infectadas por SARS-CoV-2 tienen mayores riesgos de desarrollar COVID-19 con complicaciones y de morir como consecuencia de ella. La diabetes es una condición crónica en la que se requiere continuidad de cuidados que implican un contacto con los establecimientos de salud, pues deben tener acceso regular a medicamentos, exámenes y citas con personal de salud. Esta continuidad de cuidados se ha visto afectada en el Perú a raíz de la declaratoria del estado de emergencia nacional, producto de la pandemia por la COVID-19 pues muchos establecimientos de salud han suspendido las consultas externas. Este artículo describe algunas estrategias que han desarrollado los diferentes proveedores de salud peruanos en el marco de la pandemia para proveer continuidad del cuidado a las personas con diabetes y finalmente brinda recomendaciones para que reciban los cuidados que necesitan a través del fortalecimiento del primer nivel de atención, como el punto de contacto más cercano con las personas con diabetes.

Precios de medicamentos esenciales para el manejo y tratamiento de la COVID-19 en establecimientos farmacéuticos peruanos públicos y privados / Prices of essential drugs for management and treatment of COVID-19 in public and private Peruvian pharmacies

RESUMEN Objetivo: comparar los precios de venta de medicamentos esenciales para el manejo y tratamiento de la COVID-19 en establecimientos farmacéuticos peruanos públicos y privados. Además, estimar el costo por persona del tratamiento farmacológico para casos leves y severos. Materiales y métodos: estudio transversal con información reportada por establecimientos farmacéuticos públicos y privados. El precio de los medicamentos se presenta en medianas y se compararon usando la prueba no paramétrica de Kruskal-Wallis. Además, se estimó el costo por persona y asequibilidad para el tratamiento de casos leves y severos. Resultados: medicamentos para casos leves como azitromicina, hidroxicloquina, ivermectina y paracetamol tienen medianas de precios entre S/ 0,04 (US$ 0,011) y S/ 23,81 (US$ 6,71) en establecimientos públicos, mientras que los mismos medicamentos en establecimientos privados fluctúan entre S/ 1,00 y S/ 36,00. En promedio, los precios de los medicamentos en el sector privado son 11 veces los precios en el sector público. Los costos de tratamiento por persona en establecimientos públicos son más asequibles que en los privados, especialmente para los medicamentos para casos más severos. Los esquemas de tratamiento para casos leves requieren la inversión de entre uno a cuatro días de salario mínimo. Mientras que los tratamientos de casos severos pueden requerir, hasta 64 días de salario mínimo en establecimientos privados. Conclusiones: el tratamiento farmacológico para COVID-19 supone un gasto importante para el sistema de salud público y para las familias a través de gastos de bolsillo. Urge diseñar e implementar medidas regulatorias para mejorar el acceso a medicamentos a precios asequibles.

ABSTRACT Objective: to compare the sale price of essential drugs used in the management and therapy of COVID-19 in public and private pharmacies in Peru. Also, to assess the cost per person of drug therapy for both mild and severe cases. Materials and methods: this is a cross-sectional study using data reported by public and private pharmacies in Peru. Drug prices are presented as median values and they were compared using the non-parametric Kruskal-Wallis test. Also, costs per person and drug accessibility for treating mild and moderate cases were estimated. Results: drugs used when treating mild cases of COVID-19, such as azythromycin, hydroxichloroquine, ivermectin, and paracetamol had median prices between S/ 0.04 (US$ 0.011) and S/ 23.81 (US$ 6.71) in public pharmacies, while the same compounds cost between S/ 1.00 (US$ 0.28) and S/ 36.00 (US$ 10.15) in private pharmacies. On average, drug prices in private pharmacies are 11 times higher compared to those in public pharmacies. Costs for (COVID-19) therapy in public pharmacies are more accessible compared to those found in private pharmacies, particularly for drugs used for more severely affected patients. Therapy regimens for mild cases require spending 1 to 4 days of the minimum daily wages, while therapy for severe cases (of COVID-19) may require up to 64 days of the minimum daily wages in private pharmacies. Conclusions: pharmacological treatment for COVID-19 represents an important expense for the public health system and for families through out-of-pocket expenses. It is urgent to design and implement regulatory measures aiming to improve the access to drug therapy (for Covid-19) in order to have drugs sold at accessible prices.

[Insulin: prices, availability, and affordability in public and private Peruvian pharmaciesPreço, disponibilidade e acessibilidade à insulina em farmácias públicas e privadas no Peru]. / Precios, disponibilidad y asequibilidad de insulina en farmacias públicas y privadas en Perú.

OBJECTIVE: Measure and compare the price, availability, and affordability of insulin and metformin in public and private pharmacies in six regions of Peru. METHODS: Cross-sectional study using the World Health Organization/Health Action International (WHO/HAI) revised methodology. Public and private pharmacies in six regions of Peru were surveyed. Data were collected on availability and prices for insulin (all types) and 850 mg metformin. Availability is expressed as percentages and prices are reported in medians. Affordability is defined as the number of days that a person must work at minimum wage to cover the cost of one month of treatment. RESULTS: Availability in public pharmacies is 63.2% for regular insulin and 68.4% for NPH (isophane) insulin, but differences in availability were observed between levels of care and between regions. Private pharmacies have a greater variety of insulin, but availability is less than 11%. The median price of human insulin was three to four times higher in private pharmacies than in public pharmacies. In comparison, availability of metformin was 89.5% in public pharmacies and 77.7% in private ones. Affordability in public pharmacies for one month of treatment with human insulin or generic metformin is less than one day's wages. CONCLUSIONS: The price for human insulin and generic metformin in public pharmacies is affordable. However, efforts are needed to improve their availability in the different regions and levels of care.

OBJETIVO: Avaliar o preço, a disponibilidade e a acessibilidade à insulina e metformina, como comparativo, em farmácias públicas e privadas em seis regiões do Peru. MÉTODOS: Estudo transversal conduzido com metodologia adaptada da Organização Mundial da Saúde/Ação Internacional para a Saúde (OMS/AIS). Farmácias públicas e privadas foram pesquisadas em seis regiões do Peru com a coleta de dados sobre a disponibilidade e os preços da insulina (de todos os tipos) e metformina na apresentação de 850 mg. A disponibilidade é expressa em porcentagem e os preços estão descritos como mediana. A acessibilidade foi definida no estudo como o número de dias que um indivíduo que ganha salário mínimo precisa trabalhar para arcar com o custo de um mês de tratamento. RESULTADOS: A disponibilidade em farmácias públicas da insulina regular foi de 63,2% e da insulina isófana (NPH) foi de 68,4%, porém se observou diferença de disponibilidade entre os níveis de atenção e as regiões. Nas farmácias privadas, a variedade de insulinas é maior, mas a disponibilidade é inferior a 11%. A mediana de preços para a insulina humana nas farmácias privadas é 3 a 4 vezes maior que nas farmácias públicas. Comparativamente, a disponibilidade da metformina foi de 89,5% nas farmácias públicas e 77,7% nas farmácias privadas. A acessibilidade nas farmácias públicas para um mês de tratamento com insulina humana ou metformina genérica é inferior à remuneração de um dia de trabalho. CONCLUSÕES: As insulinas humanas e a metformina genérica têm preço acessível nas farmácias públicas. Porém, esforços devem ser empreendidos para aumentar a disponibilidade destes medicamentos nos níveis de atenção e nas regiões.

Guía de práctica clínica para el diagnóstico y manejo de la osteoartritis en el Seguro Social del Perú (EsSalud) / Clinical practice guidelines for the diagnosis and management of osteoarthritis in Peruvian Social Security (EsSalud)

Este artículo resume la guía de práctica clínica (GPC) para el diagnóstico y manejo de pacientes con osteoartritis (OA) del Seguro Social del Perú (EsSalud). Para su desarrollo se conformó un grupo elaborador de la guía (GEG) que incluyó a especialistas clínicos y metodólogos. Para responder las 13 preguntas clínicas planteadas se realizaron búsquedas sistemáticas en PubMed y repositorios de GPC. Se usó la metodología Grading of Recommendations Assessment, Development, and Evaluation (GRADE) para evaluar la certeza de la evidencia. Se emitieron 11 recomendaciones: tres fuertes (no solicitar de forma rutinaria radiografías para el diagnóstico de OA, brindar un plan individualizado de medidas de educación y autocuidado, indicar la realización de ejercicio físico) y ocho débiles (intervenciones para reducir el peso en personas con obesidad o sobrepeso, evitar el uso de paracetamol para el manejo de OA, promover el uso de AINE orales para el manejo de OA, evitar el uso de condroitín sulfato para el manejo de OA, evitar el uso de proloterapia para el manejo de OA, en adultos con OA y dolor refractario a manejo farmacológico considerar terapias adyuvantes como ultrasonido o similares, evitar el uso de terapia laser como adyuvante para el manejo de OA, evitar el uso de acupuntura para el manejo de OA); además, 20 puntos de buena práctica clínica y un flujograma de trabajo.

This paper summarizes the clinical practice guideline (CPG) for the diagnosis and management of patients with osteoarthritis (OA) in the Peruvian Social Security health system (EsSalud). A working group was formed for producing this guideline, and this group included both clinical specialists and methodologists. Systematic searches in PubMed and CPG repositories were performed aiming to answer the 13 clinical questions that were asked. The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) method was used aiming to determine the certainty of evidence. Eleven recommendations were issued: three were strong (do not request X-ray films as routine practice, give an individualized plan including educational and self-care measures, and prescribe physical activity; and eight were weak (weight-reducing interventions for persons with obesity or who are overweight, avoid the use of paracetamol for OA management, promote the use of oral non-steroidal anti-inflammatory drugs for OA management, avoid the use of chondroitin sulfate for OA management, avoid the use of prolotherapy for OA management in affected adults, particularly in those with refractory pain not responding to drug therapy, consider the use of adjuvant therapy, such as ultrasound and the like, avoid the use of laser therapies as adjuvant for OA management, and avoid the use of acupuncture for OA management); also, 20 items for good clinical practice and a workflow sheet were issued.

The role of context in implementation research for non-communicable diseases: Answering the 'how-to' dilemma.

INTRODUCTION: Understanding context and how this can be systematically assessed and incorporated is crucial to successful implementation. We describe how context has been assessed (including exploration or evaluation) in Global Alliance for Chronic Diseases (GACD) implementation research projects focused on improving health in people with or at risk of chronic disease and how contextual lessons were incorporated into the intervention or the implementation process. METHODS: Using a web-based semi-structured questionnaire, we conducted a cross-sectional survey to collect quantitative and qualitative data across GACD projects (n = 20) focusing on hypertension, diabetes and lung diseases. The use of context-specific data from project planning to evaluation was analyzed using mixed methods and a multi-layered context framework across five levels; 1) individual and family, 2) community, 3) healthcare setting, 4) local or district level, and 5) state or national level. RESULTS: Project teams used both qualitative and mixed methods to assess multiple levels of context (avg. = 4). Methodological approaches to assess context were identified as formal and informal assessments, engagement of stakeholders, use of locally adapted resources and materials, and use of diverse data sources. Contextual lessons were incorporated directly into the intervention by informing or adapting the intervention, improving intervention participation or improving communication with participants/stakeholders. Provision of services, equipment or information, continuous engagement with stakeholders, feedback for personnel to address gaps, and promoting institutionalization were themes identified to describe how contextual lessons are incorporated into the implementation process. CONCLUSIONS: Context is regarded as critical and influenced the design and implementation of the GACD funded chronic disease interventions. There are different approaches to assess and incorporate context as demonstrated by this study and further research is required to systematically evaluate contextual approaches in terms of how they contribute to effectiveness or implementation outcomes.

Gaps in Guidelines for the Management of Diabetes in Low- and Middle-Income Versus High-Income Countries-A Systematic Review.

OBJECTIVE: The extent to which diabetes (DM) practice guidelines, often based on evidence from high-income countries (HIC), can be implemented to improve outcomes in low- and middle-income countries (LMIC) is a critical challenge. We carried out a systematic review to compare type 2 DM guidelines in individual LMIC versus HIC over the past decade to identify aspects that could be improved to facilitate implementation. RESEARCH DESIGN AND METHODS: Eligible guidelines were sought from online databases and websites of diabetes associations and ministries of health. Type 2 DM guidelines published between 2006 and 2016 with accessible full publications were included. Each of the 54 eligible guidelines was assessed for compliance with the Institute of Medicine (IOM) standards, coverage of the cardiovascular quadrangle (epidemiologic surveillance, prevention, acute care, and rehabilitation), translatability, and its target audiences. RESULTS: Most LMIC guidelines were inadequate in terms of applicability, clarity, and dissemination plan as well as socioeconomic and ethical-legal contextualization. LMIC guidelines targeted mainly health care providers, with only a few including patients (7%), payers (11%), and policy makers (18%) as their target audiences. Compared with HIC guidelines, the spectrum of DM clinical care addressed by LMIC guidelines was narrow. Most guidelines from the LMIC complied with less than half of the IOM standards, with 12% of the LMIC guidelines satisfying at least four IOM criteria as opposed to 60% of the HIC guidelines (P < 0.001). CONCLUSIONS: A new approach to the contextualization, content development, and delivery of LMIC guidelines is needed to improve outcomes.

Prevalence of chronic kidney disease in Peruvian primary care setting.

BACKGROUND: Chronic Kidney Disease (CKD) is a worldwide public health problem. There are few studies in Latin America, especially in primary care settings. Our objective was to determine the prevalence, stages, and associated factors of CKD in primary care setting. METHODS: We did a retrospective secondary analysis of a database from the Diabetes and Hypertension Primary Care Center of the Peruvian Social Security System (EsSalud) in Lima, Peru. We defined CKD as the presence of eGFR <60 mL/min and/or albuminuria >30 mg/day in 24 h, according to Kidney Disease: Improving Global Outcomes (KDIGO). Factors associated with CKD were evaluated with Poisson Regression models; these factors included age, gender, type 2 diabetes mellitus (DM2), hypertension (HTN), body mass index (BMI), and uric acid. Associations were described as crude and adjusted prevalence ratios (PR) and their 95% confidence intervals (95% CI). RESULTS: We evaluated 1211 patients (women [59%], mean age 65.8 years [SD: 12.7]). Prevalence of CKD was 18%. Using the estimated glomerular filtration rate (eGFR), the prevalence was 9.3% (95% CI 5.3 - 13.3) in patients without HTN or DM2; 20.2% (95% CI 17.6 - 22.8) in patients with HTN, and 23.9% (95% CI 19.4 - 28.4) in patients with DM2. The most common stages were 1 and 2 with 41.5% and 48%, respectively. Factors associated with CKD in the adjusted analysis were: age in years (PR = 1.03, 95% CI 1.01 - 1.04), DM2 (PR = 3.37, 95% CI 1.09 - 10.39), HTN plus DM2 (PR = 3.90, 95% CI 1.54 - 9.88), and uric acid from 5 to <7 mg/dL (PR = 2.04, 95% CI 1.31 - 3.19) and ≥7 mg/dL (PR = 5.19, 95% CI 3.32 - 8.11). CONCLUSIONS: Prevalence of CKD in the primary care setting population was high. CKD is more frequent in the early stages of the disease, and individuals with hypertension, DM2, older age and hyperuricemia have higher prevalence of CKD.

The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru.

BACKGROUND: Diabetes mellitus is a public health challenge worldwide, and roughly 25% of patients with diabetes in developing countries will develop at least one foot ulcer during their lifetime. The gravest outcome of an ulcerated foot is amputation, leading to premature death and larger economic costs. METHODS: This study aimed to estimate the economic costs of diabetic foot in high-risk patients in Peru in 2012 and to model the cost-effectiveness of a year-long preventive strategy for foot ulceration including: sub-optimal care (baseline), standard care as recommended by the International Diabetes Federation, and standard care plus daily self-monitoring of foot temperature. A decision tree model using a population prevalence-based approach was used to calculate the costs and the incremental cost-effectiveness ratio (ICER). Outcome measures were deaths and major amputations, uncertainty was tested with a one-way sensitivity analysis. RESULTS: The direct costs for prevention and management with sub-optimal care for high-risk diabetics is around US$74.5 million dollars in a single year, which decreases to US$71.8 million for standard care and increases to US$96.8 million for standard care plus temperature monitoring. The implementation of a standard care strategy would avert 791 deaths and is cost-saving in comparison to sub-optimal care. For standard care plus temperature monitoring compared to sub-optimal care the ICER rises to US$16,124 per death averted and averts 1,385 deaths. CONCLUSION: Diabetic foot complications are highly costly and largely preventable in Peru. The implementation of a standard care strategy would lead to net savings and avert deaths over a one-year period. More intensive prevention strategies such as incorporating temperature monitoring may also be cost-effective.